David Bailey, President & CEO of OrthoPediatrics, addressed the challenges faced in the latter part of September, particularly the delays in 7D capital sales and fluctuations in the Latin and South American markets. These factors were acknowledged as the primary reasons for the revenue shortfall against the company's expectations. Despite these hurdles, Bailey reaffirmed the commitment of OrthoPediatrics to driving profitable growth, which aims to reach cash flow break-even by 2026. He emphasized that their extensive product portfolio, comprising OPSB braces and services, positions them uniquely in the pediatric orthopedic market.